"L’IRCCS Ospedale San Raffaele è una struttura clinica-scientifica-universitaria di rilievo internazionale e di alta specializzazione per diverse importanti patologie, riconosciuta nel 1972 “Istituto di Ricovero e Cura a Carattere Scientifico” (IRCCS). La tematica della Medicina Molecolare è sempre stata l’elemento caratterizzante di questa Istituzione che ha scelto di focalizzare verso la comprensione dei processi molecolari e le applicazioni mediche delle scoperte della biologia molecolare con lo scopo di sviluppare terapie innovative per le patologie del sistema nervoso centrale e periferico, dell’apparato cardiovascolare e del metabolismo, per le patologie tumorali, le malattie infettive e immunomediate, le malattie genetiche e rare."

During the past decade, Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 3 clinical trials were completed, i.e. on average, 13.6% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 2 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 11 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 9 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored, "Gruppo Oncologico del Nord-Ovest" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" #1 collaborator was "Janssen-Cilag S.p.A." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "ERIC Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" are "Chronic Lymphocytic Leukemia" (4 trials), "Breast Cancer" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Chronic Myeloid Leukemia" (2 trials) and "AML, Adult" (1 trials). Many other conditions were trialed in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" in a lesser frequency.

Most popular intervention types in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" are "Drug" (26 trials), "Other" (4 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Venetoclax" (4 trials), "Rituximab" (3 trials), "Trastuzumab Emtansine" (3 trials), "Atezolizumab" (2 trials) and "PF-02341066" (2 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" are 30 trials for "All" genders.

Currently, there are NaN active trials in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia". 1 are not yet recruiting, 13 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".